TransMedics Group, Inc.

NasdaqGM TMDX

TransMedics Group, Inc. Price to Book Ratio (P/B) on January 14, 2025: 12.05

TransMedics Group, Inc. Price to Book Ratio (P/B) is 12.05 on January 14, 2025, a -30.47% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

TransMedics Group, Inc. 52-week high Price to Book Ratio (P/B) is 38.57 on August 27, 2024, which is 219.93% above the current Price to Book Ratio (P/B).
TransMedics Group, Inc. 52-week low Price to Book Ratio (P/B) is 11.43 on December 30, 2024, which is -5.21% below the current Price to Book Ratio (P/B).
TransMedics Group, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 24.40.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGM: TMDX

TransMedics Group, Inc.

CEO	Dr. Waleed H. Hassanein M.D.
IPO Date	May 2, 2019
Location	United States
Headquarters	200 Minuteman Road
Employees	584
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Key trends

Past 5 years